Efficacy IOP lowering and safety of Travoprost Ophthalmic Solution in Normal Tension Glaucoma patients.
Not Applicable
Recruiting
- Conditions
- Glaucoma
- Registration Number
- JPRN-UMIN000007026
- Lead Sponsor
- I.CHANGE study group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1.Complications with chronic or recurrent uveitis, scleritis, or corneal herpes. 2.History of ocular trauma or intraocular conventional surgery or laser ocular surgery in the study eye within 3 months before baseline examinations. 3.Any abnormality preventing reliable applanation tonometer in the study eye. 4.Known medical history of allergic to PGA. 5.Patients using an IOP-lowering drug other than those to be used in the study. 6.Patients using systemic administration of an oral CAI (Diamox, etc.) 7.Patient having serious eyes complications 8.Women who are pregnant or lactating. 9.Patients who are judged to be inappropriate for participation in the study for other reason by the doctor in charge.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy IOP value; IOP-lowering effect from baseline (reduced value; reduction rate%)
- Secondary Outcome Measures
Name Time Method Safety 1.Ocular safety assessment:Conjunctival hyperemia, adverse events 2.Systemic safety assessment:adverse events